PYGL

Across TCGA pan-cancer cohorts, PYGL mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PYGL data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PYGL mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PYGL expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where PYGL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.672	0.851	<.001	57	view →
HNSC	OS	Median	All	0.926	0.762	.001	28	view →
LUAD	OS	Tertile	III,IV	0.165	0.840	.003	23	view →
GBM	DFS	Median	All	0.657	0.840	.008	6	view →
CCRCC	DFS	Median	III,IV	1.000	0.451	.032	4	view →
UCEC	OS	Quartile	All	0.846	1.000	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PYGL–PDAC (DFS)

Open the PDAC breakdown →